Preventive stenting in acute myocardial infarction

Ari Pollack, Bibhu Mohanty, Rishi Handa, Patrick M. Looser, Valentin Fuster, Spencer B. King, Samin K. Sharma

Research output: Contribution to journalReview article

Abstract

Current practice guidelines advocate culprit vessel intervention alone in patients with ST-segment elevation myocardial infarction (STEMI) found to have multivessel coronary disease during primary percutaneous coronary intervention (PCI). The debate on the timing of noninfarct artery intervention has recently been reinvigorated by the PRAMI (Preventive Angioplasty in Acute Myocardial Infarction) trial, in which patients undergoing preventive PCI of significant nonculprit lesions at the time primary PCI for STEMI had reduced rates of cardiac death, nonfatal myocardial infarction, and refractory angina. Given that previous literature has cautioned against multivessel PCI during STEMI, this raises the question of whether technical and pharmacological advances in PCI may have opened the door to safely revisit this issue with additional clinical rigor. The impact of STEMI pathophysiology on nonculprit vessel plaque, how treatment of nonculprit lesions alters the natural history of coronary disease after STEMI, and whether this results in a clinical benefit remain unclear, and much of the existing data are retrospective. Additionally, the PRAMI trial did not include a staged PCI, leaving questions as to how this approach might fare compared with simultaneous preventive PCI. In this review, we discuss the pathophysiology of nonculprit vessel plaque in STEMI, provide a summary of the existing literature on the topic, and discuss the PRAMI trial in the face of previous data and possible future directions for further study.

Original languageEnglish (US)
Pages (from-to)131-138
Number of pages8
JournalJACC: Cardiovascular Interventions
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Percutaneous Coronary Intervention
Myocardial Infarction
Angioplasty
Coronary Disease
Practice Guidelines
Arteries
Pharmacology

Keywords

  • Multivessel pci
  • Preventive angioplasty
  • STEMI

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Pollack, A., Mohanty, B., Handa, R., Looser, P. M., Fuster, V., King, S. B., & Sharma, S. K. (2015). Preventive stenting in acute myocardial infarction. JACC: Cardiovascular Interventions, 8(1), 131-138. https://doi.org/10.1016/j.jcin.2014.09.006

Preventive stenting in acute myocardial infarction. / Pollack, Ari; Mohanty, Bibhu; Handa, Rishi; Looser, Patrick M.; Fuster, Valentin; King, Spencer B.; Sharma, Samin K.

In: JACC: Cardiovascular Interventions, Vol. 8, No. 1, 01.01.2015, p. 131-138.

Research output: Contribution to journalReview article

Pollack, A, Mohanty, B, Handa, R, Looser, PM, Fuster, V, King, SB & Sharma, SK 2015, 'Preventive stenting in acute myocardial infarction', JACC: Cardiovascular Interventions, vol. 8, no. 1, pp. 131-138. https://doi.org/10.1016/j.jcin.2014.09.006
Pollack A, Mohanty B, Handa R, Looser PM, Fuster V, King SB et al. Preventive stenting in acute myocardial infarction. JACC: Cardiovascular Interventions. 2015 Jan 1;8(1):131-138. https://doi.org/10.1016/j.jcin.2014.09.006
Pollack, Ari ; Mohanty, Bibhu ; Handa, Rishi ; Looser, Patrick M. ; Fuster, Valentin ; King, Spencer B. ; Sharma, Samin K. / Preventive stenting in acute myocardial infarction. In: JACC: Cardiovascular Interventions. 2015 ; Vol. 8, No. 1. pp. 131-138.
@article{75e522b3e32b45cdb4ba94bcfe981783,
title = "Preventive stenting in acute myocardial infarction",
abstract = "Current practice guidelines advocate culprit vessel intervention alone in patients with ST-segment elevation myocardial infarction (STEMI) found to have multivessel coronary disease during primary percutaneous coronary intervention (PCI). The debate on the timing of noninfarct artery intervention has recently been reinvigorated by the PRAMI (Preventive Angioplasty in Acute Myocardial Infarction) trial, in which patients undergoing preventive PCI of significant nonculprit lesions at the time primary PCI for STEMI had reduced rates of cardiac death, nonfatal myocardial infarction, and refractory angina. Given that previous literature has cautioned against multivessel PCI during STEMI, this raises the question of whether technical and pharmacological advances in PCI may have opened the door to safely revisit this issue with additional clinical rigor. The impact of STEMI pathophysiology on nonculprit vessel plaque, how treatment of nonculprit lesions alters the natural history of coronary disease after STEMI, and whether this results in a clinical benefit remain unclear, and much of the existing data are retrospective. Additionally, the PRAMI trial did not include a staged PCI, leaving questions as to how this approach might fare compared with simultaneous preventive PCI. In this review, we discuss the pathophysiology of nonculprit vessel plaque in STEMI, provide a summary of the existing literature on the topic, and discuss the PRAMI trial in the face of previous data and possible future directions for further study.",
keywords = "Multivessel pci, Preventive angioplasty, STEMI",
author = "Ari Pollack and Bibhu Mohanty and Rishi Handa and Looser, {Patrick M.} and Valentin Fuster and King, {Spencer B.} and Sharma, {Samin K.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.jcin.2014.09.006",
language = "English (US)",
volume = "8",
pages = "131--138",
journal = "JACC: Cardiovascular Interventions",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Preventive stenting in acute myocardial infarction

AU - Pollack, Ari

AU - Mohanty, Bibhu

AU - Handa, Rishi

AU - Looser, Patrick M.

AU - Fuster, Valentin

AU - King, Spencer B.

AU - Sharma, Samin K.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Current practice guidelines advocate culprit vessel intervention alone in patients with ST-segment elevation myocardial infarction (STEMI) found to have multivessel coronary disease during primary percutaneous coronary intervention (PCI). The debate on the timing of noninfarct artery intervention has recently been reinvigorated by the PRAMI (Preventive Angioplasty in Acute Myocardial Infarction) trial, in which patients undergoing preventive PCI of significant nonculprit lesions at the time primary PCI for STEMI had reduced rates of cardiac death, nonfatal myocardial infarction, and refractory angina. Given that previous literature has cautioned against multivessel PCI during STEMI, this raises the question of whether technical and pharmacological advances in PCI may have opened the door to safely revisit this issue with additional clinical rigor. The impact of STEMI pathophysiology on nonculprit vessel plaque, how treatment of nonculprit lesions alters the natural history of coronary disease after STEMI, and whether this results in a clinical benefit remain unclear, and much of the existing data are retrospective. Additionally, the PRAMI trial did not include a staged PCI, leaving questions as to how this approach might fare compared with simultaneous preventive PCI. In this review, we discuss the pathophysiology of nonculprit vessel plaque in STEMI, provide a summary of the existing literature on the topic, and discuss the PRAMI trial in the face of previous data and possible future directions for further study.

AB - Current practice guidelines advocate culprit vessel intervention alone in patients with ST-segment elevation myocardial infarction (STEMI) found to have multivessel coronary disease during primary percutaneous coronary intervention (PCI). The debate on the timing of noninfarct artery intervention has recently been reinvigorated by the PRAMI (Preventive Angioplasty in Acute Myocardial Infarction) trial, in which patients undergoing preventive PCI of significant nonculprit lesions at the time primary PCI for STEMI had reduced rates of cardiac death, nonfatal myocardial infarction, and refractory angina. Given that previous literature has cautioned against multivessel PCI during STEMI, this raises the question of whether technical and pharmacological advances in PCI may have opened the door to safely revisit this issue with additional clinical rigor. The impact of STEMI pathophysiology on nonculprit vessel plaque, how treatment of nonculprit lesions alters the natural history of coronary disease after STEMI, and whether this results in a clinical benefit remain unclear, and much of the existing data are retrospective. Additionally, the PRAMI trial did not include a staged PCI, leaving questions as to how this approach might fare compared with simultaneous preventive PCI. In this review, we discuss the pathophysiology of nonculprit vessel plaque in STEMI, provide a summary of the existing literature on the topic, and discuss the PRAMI trial in the face of previous data and possible future directions for further study.

KW - Multivessel pci

KW - Preventive angioplasty

KW - STEMI

UR - http://www.scopus.com/inward/record.url?scp=84921381343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921381343&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2014.09.006

DO - 10.1016/j.jcin.2014.09.006

M3 - Review article

C2 - 25616917

AN - SCOPUS:84921381343

VL - 8

SP - 131

EP - 138

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

SN - 1936-8798

IS - 1

ER -